Slingshot members are tracking this event:

Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa in Patients With Elevated Triglycerides Despite Statin Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMRN Community voting in process

Additional Information

Additional Relevant Details Target patient enrollment has been reached in the REDUCE-IT cardiovascular outcomes trial of Vascepa (icosapent ethyl). Amarin also announced that the onset of approximately 60% of the target aggregate number of primary cardiovascular events within the REDUCE-IT study has triggered preparation for a pre-specified interim efficacy and safety analysis by the independent Data Monitoring Committee (DMC). Amarin currently expects the independent interim analysis to be conducted in approximately six months.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 31, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vascepta, Triglycerides, Statin Therapy, Icosapent Ethyl